Eagle Health Investments LP Raises Stake in Compass Pathways PLC Sponsored ADR $CMPS

Eagle Health Investments LP boosted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 62.4% during the 4th quarter, HoldingsChannel reports. The firm owned 1,519,388 shares of the company’s stock after purchasing an additional 583,938 shares during the period. Compass Pathways accounts for approximately 2.3% of Eagle Health Investments LP’s investment portfolio, making the stock its 15th biggest holding. Eagle Health Investments LP’s holdings in Compass Pathways were worth $10,484,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Raymond James Financial Inc. grew its position in Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the last quarter. Advisory Services Network LLC purchased a new position in Compass Pathways during the 3rd quarter worth $41,000. BIT Capital GmbH purchased a new position in Compass Pathways during the 3rd quarter worth $54,000. Bank of America Corp DE grew its position in Compass Pathways by 65.0% during the 3rd quarter. Bank of America Corp DE now owns 30,498 shares of the company’s stock worth $175,000 after purchasing an additional 12,017 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC purchased a new position in Compass Pathways during the 4th quarter worth $104,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. UBS Group set a $18.00 price objective on shares of Compass Pathways in a research report on Thursday, May 7th. Compass Point set a $15.00 target price on shares of Compass Pathways in a report on Thursday, February 12th. Jefferies Financial Group raised shares of Compass Pathways to a “strong-buy” rating in a report on Tuesday, May 5th. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.58.

Compass Pathways News Summary

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Compass Pathways, while raising multiple earnings estimates across 2026 and 2027. The broker’s higher forecasts suggest improving longer-term fundamentals and may be helping support the stock. Compass Pathways analyst estimate updates
• Positive Sentiment: Recent articles also point to retail trader optimism that a major FDA-related catalyst could be brewing, adding momentum to the shares and fueling breakout-style buying interest. CMPS stock is breaking out again — retail traders think a major FDA catalyst is brewing
• Neutral Sentiment: HC Wainwright’s revisions were mixed in direction across periods, but the overall message remained constructive: near-term losses are still expected, yet the firm sees a path to improving earnings over time.

Compass Pathways Stock Up 7.9%

Shares of NASDAQ:CMPS opened at $10.87 on Thursday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -3.45 and a beta of 2.39. The firm’s 50-day simple moving average is $7.45 and its 200-day simple moving average is $6.83. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $11.65.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.97 earnings per share for the current year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.